DrugPatentWatch Database Preview
TECHNIVIE Drug Profile
Email this page to a colleague
» See Plans and PricingWhen do Technivie patents expire, and when can generic versions of Technivie launch?
Technivie is a drug marketed by Abbvie Inc and is included in one NDA. There are ten patents protecting this drug.
This drug has four hundred and thirty-six patent family members in forty-seven countries.
The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.
US ANDA Litigation and Generic Entry Outlook for Technivie
Technivie was eligible for patent challenges on December 19, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be April 13, 2032. This may change due to patent challenges or generic licensing.
There have been fifteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for TECHNIVIE
| International Patents: | 436 |
| US Patents: | 10 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 1 |
| Clinical Trials: | 2 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for TECHNIVIE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TECHNIVIE |
| DailyMed Link: | TECHNIVIE at DailyMed |
Generic Entry Opportunity Date for TECHNIVIE
Generic Entry Date for TECHNIVIE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for TECHNIVIE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AbbVie | Phase 3 |
Recent Litigation for TECHNIVIE
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| AbbVie Inc. v. Cipla Limited | 2017-11-10 |
| AbbVie Inc. v. Aurobindo Pharma Limited | 2017-01-13 |
| AbbVie Inc. v. Amneal Pharmaceuticals, LLC | 2016-05-27 |
Synonyms for TECHNIVIE
| Ombitasvir / paritaprevir / ritonavir |
| Ombitasvir and paritaprevir and ritonavir |
| Ombitasvir mixture with paritaprevir and ritonavir |
| S900007110 |
US Patents and Regulatory Information for TECHNIVIE
Expired US Patents for TECHNIVIE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | Start Trial | Start Trial |
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | Start Trial | Start Trial |
| Abbvie Inc | TECHNIVIE | ombitasvir; paritaprevir; ritonavir | TABLET;ORAL | 207931-001 | Jul 24, 2015 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TECHNIVIE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | 201347759 | Start Trial |
| Cyprus | 1120780 | Start Trial |
| Denmark | 2628481 | Start Trial |
| Norway | 2015012 | Start Trial |
| Hong Kong | 1186415 | Start Trial |
| Malaysia | 164607 | Start Trial |
| Slovenia | 2283844 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for TECHNIVIE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2692346 | C20170036 00243 | Estonia | Start Trial | PRODUCT NAME: PIBRENTASVIIR;REG NO/DATE: EU/1/17/1213 28.07.2017 |
| 2340029 | C02340029/01 | Switzerland | Start Trial | PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: SWISSMEDIC 65301 25.11.2014 |
| 2692346 | PA2017033 | Lithuania | Start Trial | PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726 |
| 2368890 | CA 2015 00015 | Denmark | Start Trial | PRODUCT NAME: OMBITASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/14/982 20150115 |
| 2340029 | 1590012-9 | Sweden | Start Trial | PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REG. NO/DATE: EU/1/14/982 20150119 |
| 2692346 | LUC00038 | Luxembourg | Start Trial | PRODUCT NAME: PIBRENTASVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1213 20170728 |
| 2692346 | 122017000074 | Germany | Start Trial | PRODUCT NAME: PIBRENTASVIR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1213 20170726 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
